Market Research Logo

Relapsing Remitting Multiple Sclerosis (RRMS) Global Clinical Trials Review, H1, 2018

Relapsing Remitting Multiple Sclerosis (RRMS) Global Clinical Trials Review, H1, 2018

Summary

GlobalData's clinical trial report, “Relapsing Remitting Multiple Sclerosis (RRMS) Global Clinical Trials Review, H1, 2018 provides an overview of Relapsing Remitting Multiple Sclerosis (RRMS) clinical trials scenario. This report provides top line data relating to the clinical trials on Relapsing Remitting Multiple Sclerosis (RRMS). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


  • Report Guidance
  • GlobalData Clinical Trials Report Coverage
  • Clinical Trials by Region
    • Table Figure 1: Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, Global, Clinical Trials by Region (%), 2018*
    • Table Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, Global, Clinical Trials by Region, 2018*
    • Clinical Trials and Average Enrollment by Country
      • Table Figure 2: Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018*
      • Table Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018*
      • Table Figure 3: Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018*
      • Table Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018*
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
        • Table Figure 4: Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018*
        • Table Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018*
      • Top Five Countries Contributing to Clinical Trials in Europe
        • Table Figure 5: Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018*
        • Table Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Europe, Top Five Countries, 2018*
      • Top Countries Contributing to Clinical Trials in North America
        • Table Figure 6: Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, North America, Top Countries (%), 2018*
        • Table Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, North America, Top Countries, 2018*
      • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
        • Table Figure 7: Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018*
        • Table Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018*
      • Top Five Countries Contributing to Clinical Trials in Central and South America
        • Table Figure 8: Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018*
        • Table Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018*
  • Clinical Trials by G7 Countries: Proportion of Relapsing Remitting Multiple Sclerosis (RRMS) to Central Nervous System Clinical Trials
    • Table Figure 9: Proportion of Relapsing Remitting Multiple Sclerosis (RRMS) to Central Nervous System Clinical Trials, G7 Countries (%), 2018*
    • Table Proportion of Relapsing Remitting Multiple Sclerosis (RRMS) to Central Nervous System Clinical Trials, G7 Countries (%), 2018*
  • Clinical Trials by Phase in G7 Countries
    • Table Figure 10: Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018*
    • Table Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018*
  • Clinical Trials in G7 Countries by Trial Status
    • Table Figure 11: Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018*
    • Table Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018*
  • Clinical Trials by E7 Countries: Proportion of Relapsing Remitting Multiple Sclerosis (RRMS) to Central Nervous System Clinical Trials
    • Table Figure 12: Proportion of Relapsing Remitting Multiple Sclerosis (RRMS) to Central Nervous System Clinical Trials, E7 Countries (%), 2018*
    • Table Proportion of Relapsing Remitting Multiple Sclerosis (RRMS) to Central Nervous System Clinical Trials, E7 Countries (%), 2018*
  • Clinical Trials by Phase in E7 Countries
    • Table Figure 13: Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018*
    • Table Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018*
  • Clinical Trials in E7 Countries by Trial Status
    • Table Figure 14: Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018*
    • Table Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018*
  • Clinical Trials by Phase
    • Table Figure 15: Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, Global, Clinical Trials by Phase (%), 2018*
    • Table Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, Global, Clinical Trials by Phase, 2018*
    • In Progress Trials by Phase
      • Table Figure 16: Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, Global, Clinical Trials In Progress by Phase, 2018*
      • Table Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, Global, Clinical Trials In Progress by Phase 2018*
  • Clinical Trials by Trial Status
    • Table Figure 17: Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, Global, Clinical Trials by Trial Status, 2018*
    • Table Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics, Global, Clinical Trials by Trial Status, 2018*
  • Clinical Trials by End Point Status
    • Table Figure 18: Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Global, by End Point Status, 2018*
    • Table Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Global, by End Point Status, 2018*
  • Subjects Recruited Over a Period of Time
    • Table Figure 19: Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017
    • Table Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017
  • Clinical Trials by Sponsor Type
    • Table Figure 20: Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018*
    • Table Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018*
  • Prominent Sponsors
    • Table Figure 21: Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Global, Key Sponsors, 2018*
    • Table Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Global, Key Sponsors, 2018*
    • Top Companies Participating in Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials
      • Table Figure 22: Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018*
      • Table Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018*
  • Prominent Drugs
    • Table Figure 23: Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018*
    • Table Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018*
  • Latest Clinical Trials News on Relapsing Remitting Multiple Sclerosis (RRMS)
    • Jun 18, 2018: Data Provide Further Insight Into the Consistent Efficacy Benefits of Mavenclad in Relapsing MS
    • Apr 23, 2018: Treatment Effects Maintained over Seven Years in Patients with Relapsing Remitting Multiple Sclerosis Who Received Lemtrada (alemtuzumab) in Clinical Trials
    • Apr 21, 2018: Mylan Presents Equivalence Data on Glatiramer Acetate Compared to Copaxone at American Academy of Neurology 70th Annual Meeting
    • Apr 19, 2018: Sanofi Genzyme's Multiple Sclerosis Data to Be Featured at AAN
    • Apr 17, 2018: Teva to Present New Data on COPAXONE at 70th Annual Meeting of the American Academy of Neurology
    • Apr 13, 2018: EMD Serono Highlights Commitment to Advance Multiple Sclerosis Treatment with Investigational Cladribine Tablets
    • Apr 13, 2018: EMD Serono Highlights Commitment to Advance Multiple Sclerosis Treatment with Investigational Rebif Data at AAN 2018
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
      • Table Figure 24: GlobalData Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report